We are live on ! Find out more
LUMO

Lumos Pharma, Inc. Common Stock

Delisted

LUMO was delisted on the 11th of December, 2024.

122 hedge funds and large institutions have $145M invested in Lumos Pharma, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 37 increasing their positions, 36 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

398% more call options, than puts

Call options by funds: $13.3M | Put options by funds: $2.68M

164% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 11

17% more funds holding

Funds holding: 104122 (+18)

3% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 36

28% less capital invested

Capital invested by funds: $202M → $145M (-$57.6M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
122
Holders Change
+18
Holders Change %
+17.31%
% of All Funds
3.05%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
29
Increased
37
Reduced
36
Closed
11
Calls
$13.3M
Puts
$2.68M
Net Calls
+$10.7M
Net Calls Change
-$2.59M
Name Holding Trade Value Shares
Change
Change in
Stake
First Eagle Investment Management
1
First Eagle Investment Management
New York
$21.9M -$720K -6,389 -3%
O
2
OrbiMed
New York
$20.5M +$669K +5,933 +3%
BFA
3
BlackRock Fund Advisors
California
$11.5M +$1.6M +14,156 +13%
Vanguard Group
4
Vanguard Group
Pennsylvania
$9.34M +$310K +2,747 +3%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$9.3M +$6.16M +54,704 +119%
BIT
6
BlackRock Institutional Trust
California
$5.57M +$184K +1,635 +3%
Millennium Management
7
Millennium Management
New York
$5.49M +$2.03M +18,034 +44%
Franklin Resources
8
Franklin Resources
California
$5.3M
State Street
9
State Street
Massachusetts
$4.42M +$288K +2,558 +6%
Northern Trust
10
Northern Trust
Illinois
$2.87M +$82.8K +735 +2%
SBH
11
Segall Bryant & Hamill
Illinois
$2.09M -$617K -5,478 -19%
TA
12
Teachers Advisors
New York
$2.08M +$68.9K +611 +3%
Deutsche Bank
13
Deutsche Bank
Germany
$1.89M -$1.79M -15,921 -44%
BIM
14
Bogle Investment Management
Massachusetts
$1.81M -$545K -4,833 -20%
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$1.75M -$579K -5,137 -21%
Wells Fargo
16
Wells Fargo
California
$1.63M +$94.5K +839 +5%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$1.63M +$151K +1,343 +8%
Renaissance Technologies
18
Renaissance Technologies
New York
$1.5M -$2.52M -22,333 -58%
QI
19
QS Investors
New York
$1.48M -$493K -4,378 -21%
CCI
20
Columbus Circle Investors
$1.38M +$316K +2,804 +23%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$1.3M -$249K -2,214 -14%
Morgan Stanley
22
Morgan Stanley
New York
$1.28M +$1.3M +11,565 +507%
D.E. Shaw & Co
23
D.E. Shaw & Co
New York
$1.16M +$1.06M +9,363 +290%
WSA
24
Wall Street Associates
California
$1.12M -$498K -4,422 -27%
SCA
25
Secor Capital Advisors
New York
$1.03M +$412K +3,658 +49%

LUMO Hedge Fund Activity: Q4 2016 in Review

122 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q4 2016, worth a combined $145M — down 28% from $202M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new LUMO positions and 11 closed out — a net gain of 18 holders — while 37 added to existing stakes and 36 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $6.16M. The largest seller was HAP Trading, exiting entirely with an estimated $3.73M sold.

  • 122 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q4 2016, up from 104 in Q3 2016.
  • Funds reported $145M of Lumos Pharma, Inc. Common Stock stock for Q4 2016, down 28% quarter-over-quarter.
  • 29 funds opened new Lumos Pharma, Inc. Common Stock positions in Q4 2016 and 11 closed out, a net change of +18 holders.
  • The largest Lumos Pharma, Inc. Common Stock buyer in Q4 2016 was Fidelity Investments, an estimated $6.16M added.
  • The largest Lumos Pharma, Inc. Common Stock seller in Q4 2016 was HAP Trading, an estimated $3.73M sold.

Based on aggregated 13F filings for Q4 2016.